











































Autophagy as a novel therapeutic target in vascular calcification
Citation for published version:
Phadwal, K, Feng, D, Zhu, D & MacRae, V 2019, 'Autophagy as a novel therapeutic target in vascular
calcification', Pharmacology and Therapeutics. https://doi.org/10.1016/j.pharmthera.2019.107430
Digital Object Identifier (DOI):
10.1016/j.pharmthera.2019.107430
Link:






Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
Pharmacology & Therapeutics-PT-23593 
 
Authors’ response to reviewers’ comments 
 
Dear Dr. Curtis, 
 
We are extremely grateful for your prompt dealing with our review article entitled ‘Autophagy as 
a novel therapeutic target in vascular calcification’. We are pleased to submit the revised 
manuscript now for your consideration. 
 
We thank the reviewers for their highly constructive comments and suggestions, and we have 
revised our manuscript accordingly. This has entailed editing and adding new text, which are 
highlighted in red. We have also listed each of reviewers’ comments and provided our detailed 
response as below. 
 
We believe our manuscript is much improved and we hope that it is now considered suitable 




On behalf of the authors, 
 
Dr. Dongxing Zhu 
 
 
Authors’ response to reviewers’ comments 
 
Reviewer 1  
 
1. Is the sense of it logical or is it clunky (example)? 
The Review is well written in a Logical way. In my view the Review would benefit from just 
focusing on media calcification (calcification on VSMC) rather than mixing it up with 
atherosclerosis and valvular calcification. It is often mixed in the text and thereby not logic to 
follow. Additionally, the Authors only mention VSMC calcification in their Abstract! 
Authors’ response: We thank the reviewer for their consideration of this point. We have removed 
the text in section 3.1 on endothelial cells, section 4.1 describing the role of autophagy in plaque 
necrosis in atherosclerosis, and the entire section 4.4 autophagy in calcific aortic valve disease 
(CAVD). Our review manuscript is now focused on vascular media calcification. 
 
2. Is it all necessary or can some of it be deleted as ‘off topic’ (examples)? 
As mentioned above it would be important to follow VSMC calcification rather than a mixture 
of very different disease entities. I still believe that media sclerosis and arteriosclerosis are 
very different diseases. 
Authors’ response: We thank the reviewer for highlighting this point. We agree with the reviewer 
that media sclerosis and arteriosclerosis are very different diseases, although they may share 
some similar common mechanisms. As described above, we have removed the text in section 3.1, 
section 4.1 and the entire section 4.4 to focus our manuscript on vascular medial calcification. 
 
3. Is it comprehensive or have they missed citing anything important (examples)? 
It should be clearly stated that there are mTOR dependent and independent ways of inducing 
autophagy. The Review would benefit to show differences and overlaps of apoptosis, necrosis, 
necroptosis and autophagy. 
Authors’ response: We thank the reviewer for consideration of this point. We have stated both 
the TOR dependent and independent autophagy pathways under section 2-The key regulators of 
autophagy. Under the same section we have also added text on cell death and autophagic cell 
death and its crosstalk with apoptosis. As commented by reviewer 2, it is not mTOR in yeast, but 
TOR. We have revised this term accordingly. The additional text has been added as below (Page 7, 
line 14-23). 
Furthermore, autophagy pathway could also be regulated by TOR independent pathways like 
inositol signalling pathways (Sarkar, et al., 2005), Ca2+/calpain pathway (Williams, et al., 2008), 
cAMP pathway (Williams, et al., 2008) etc. It is also interesting to note that autophagy pathway, 
which is mainly a cellular degradation pathway is intimately linked to cell death and is different 
from other programmed cell death mechanisms like apoptosis, necrosis and necroptosis. 
Autophagy cell death is often seen associated with increased number of autophagosomes inside 
the cell (Yonekawa & Thorburn, 2013). However, there is a complex crosstalk between autophagy 
and apoptosis where the calpain-mediated cleavage of Atg5 can trigger cell death by apoptosis 







Page 5 – Fix none to non in the following sentence: “In this review we focus on macroautophagy 
(referred hereafter as autophagy) which could be both selective or none selective on the basis of 
the cargo engulfed.” 
Authors’ response: This has been corrected, Page 5, line 9-15. 
 
Please be clearer about the difference between selective and non-selective autophagy (i.e 
degrading cytosolic components vs. bulk degradation). “On the basis of the cargo engulfed” 
makes it sound like only certain organelles (such as mitochondria and peroxisomes) can be 
degraded by selective autophagy but not others (like the ER). Do you mean to say selective 
autophagy can be regulated by different autophagy receptors depending on the organelle? 
Authors’ response: We thank the reviewer for consideration of this point. Additional text has 
been added under introduction as below to describe both the selective and non-selective 
autophagy, Page 5, line 10-16. 
In this review we focus on macroautophagy (referred hereafter as autophagy) which could be 
both selective and non-selective. Non-selective autophagy degrades cytoplasmic contents, 
however selective autophagy can degrade specific substrates like mitochondria (Lazarou, et al., 
2015), ribosomes (Kraft, Deplazes, Sohrmann, & Peter, 2008), bits of ER (Wilkinson, 2019), 
peroxisomes (Kim, Hailey, Mullen, & Lippincott-Schwartz, 2008), bacteria (Bauckman, 
Owusu-Boaitey, & Mysorekar, 2015) etc. using specific autophagy receptors. 
 
2. The key regulators of autophagy               
• Page 6 – Though the authors are correct in saying most of the initial molecular work on 
autophagy was carried out in yeast, for this review the authors should focus on mammalian genes 
and proteins. I found it confusing when the authors talk about mammalian Target of Rapamycin, 
but then mention the yeast proteins (it is not mTOR in yeast, but TOR). 
Authors’ response: This has been corrected from mTOR to TOR (Page 6, line14).  
 
• Page 7 – Add the following references found in text (Fimia, Kroemer, & Piacentini, 2013) and 
(Dikic and Elazar, 2018, Kaur and Debnath, 2015, Mizushima, 2007) in the reference list. 
Authors’ response: These references are now added on Page 20-23. 
 
3. Autophagy in maintenance of vascular cell function 
• Page 7 – Define ECs and VSMCs in text 
Authors’ response: We have defined VSMCs in text (Page 8, line1). The endothelial cell section 
has been removed as suggested by Reviewer 1. 
 
• Figure 1 – Phagophore assembly – Vps15 and Atg6 are listed in text but missing in figure (as 
previously mentioned though, please stick to mammalian proteins, i.e Beclin1 not Atg6) 
Authors’ response: These corrections are now made in our revised Figure 1.   
 
 Autophagosome expansion and completion – Atg16 and Atg10 are listed in text but missing 
in figure. 
Authors’ response: These corrections are now made in our revised Figure 1.   
 
• Autophagosome lysosome fusion - Include LC3-PE complex on autophagosome surface. 
LAMP-I and LAMP-II are not discussed in text but are in the figure. Do these need to be in the 
figure? 
Authors’ response: We have included LC3-PE complex on autophagosome surface, and we have 
removed LAMP-I and LAMP-II from revised Figure 1. 
 
• Refer to each part of the figure (a,b,c and d) as discussed in order in the text. 
Authors’ response: We have now referred to each part of the Figure 1 under section 2-The key 
regulators of autophagy (Page 6-7). 
 
•  Figure 2 – Label cell on figure (is it VSMC?) 
Authors’ response: The cells are now labelled as VSMC in revised Figure 2. 
 
• Perhaps rearrange figure so that ‘PDGR and high Pi’ are placed above b. Cytoprotective 
Autophagy heading to make the cause of this autophagy clear 
Authors’ response: We have rearranged the Figure 2 accordingly. 
 
• Label cell as ‘healthy’ not health 
Authors’ response: The cell is now labeled as Healthy VSMC in revised Fig 2.  
 
• The induction of autophagy by oestrogen, rapamycin and metformin is not mentioned in text 
and is not referenced.  
Authors’ response: We have described and referenced the induction of autophagy by oestrogen, 
rapamycin and metformin in our revised manuscript. 
 
Page 12, line 5-7: Treatment with rapamycin significantly reduced aortic calcification and release 
of pro-inflammatory cytokines including tumour necrosis factor alpha (TNF-α) and Interleukin 6 
(IL-6), with enhanced survival noted in these mice (Frauscher et al., 2018). 
 
Page 16, line 5-8: Interestingly metformin, (used to treat type 2 diabetes),  has been shown to 
induce autophagy to restore β-GP-induced impairment of mitochondrial biogenesis and apoptosis 
in VSMCs, along with blocking the phenotypic transition of VSMCs (Ma, et al., 2019) (Fig 2).   
 
Page 17, line 2-8: Furthermore, treatment with estrogen attenuates arterial calcification by 
blocking the osteoblastic differentiation of VSMCs and this is via induction of the autophagy 
pathway (Peng, et al., 2017) (Fig 2). This protective effect of estrogen treatment is enhanced by 
the addition of rapamycin (Peng, et al., 2017) (Fig 2). 
 
Additionally, rapamycin has been reported to inhibit vascular calcification in the DBA/2 diabetic 
mouse model (Frauscher, et al., 2018). 
 
• The accumulation of ROS in the cell suggests there is more in the cells as a result of 
cytoprotective autophagy. 
Authors’ response: We have changed the colour for ROS in revised Figure 2, so that it looks 
distinctive from cytoprotective autophagy. 
 
• New information is presented in the figure legend and not discussed in text and also not 
referenced. Please discuss in text and refer to the figure accordingly. 
Authors’ response: Both the Figure 2 legend and text has been modified accordingly as suggested 
by the reviewer (Page 8-10, and Page 15-17).  
 
• Is High Pi intracellular or extracellular which leads to cytoprotective autophagy? 
Authors’ response: Intracellular Pi leads to cytoprotective autophagy. Dai et al has reported that 
knockdown of the sodium-dependent phosphate cotransporter Pit1 attenuates high Pi-induced 
autophagy in VSMCs. Pit1 plays an important role in transporting extracellular phosphate into 
intracellular space. It has been mentioned in our manuscript and revised Figure 2 legend (Page 10, 
line 24-25). 
High Pi increases PiT-1 expression, which leads to elevated levels of intracellular Pi. This further 
enhances Runx2 expression and the osteogenic transition of VSMCs (Fig 2). 
Reference in our manuscript: Dai, X. Y., Zhao, M. M., Cai, Y., Guan, Q. C., Zhao, Y., Guan, Y., Kong, 
W., Zhu, W. G., Xu, M. J., & Wang, X. (2013). Phosphate-induced autophagy counteracts vascular 
calcification by reducing matrix vesicle release. Kidney Int, 83, 1042-1051. 
 
• Page 9 - (Shao, et al., 2014) – is this the correct reference to put here? 
Authors’ response: We are sorry for the wrong reference, and it has been removed accordingly. 
 
• Page 10 – Elaborate on the mechanism by which autophagy regulates Ca2+ homeostasis in 
VSMCs. Is the exact mechanism known? 
Authors’ response: To the best of our knowledge, there is currently only one paper which has 
investigate Ca2+ homeostasis in mouse model with VSMC specific deletion of Atg7 (Atg7fl/fl 
SM22α-Cre+) (Micheils et al 2015). This paper has been discussed in our manuscript, Page 9, line 
12-24.  
It has been shown that increased cytosolic concentrations of Ca2+ (e.g. Thapsigargin treatment) 
induces autophagosome formation both by TOR dependent and independent pathways (Williams, 
et al., 2008). However, this increase in autophagosome numbers does not leads to enhanced 
autophagy, rather  causes a decline in autophagic clearance via lysosomes (Ganley, Wong, 
Gammoh, & Jiang, 2011). The reasons behind autophagy impairment under increased calcium 
concentrations remains to be elucidated. Interestingly autophagy is shown to regulate Ca2+ 
homeostasis in VSMCs. VSMC specific deletion of Atg7 (Atg7fl/fl SM22α-Cre+) in mice causes an 
imbalance between Ca2+ uptake and Ca2+ release. The voltage-gated Ca2+ channels which 
promotes Ca2+ entry inside the cell from the extracellular space were more sensitive to 
depolarisation (open for Ca2+ entry from extracellular space) in autophagy defective VSMCs. On 
the contrary there was reduced expression of the plasma membrane Ca2+ ATPase required for 
removal of Ca2+ to extracellular space, leading to elevated basal levels of intracellular Ca2+ levels 
inside the cell (Michiels, Fransen, De Munck, De Meyer, & Martinet, 2015). 
 
4. Autophagy in cardiovascular calcification 
• Page 11 – “…the MVs released from osteogenic cells facilitate hydroxyapatite formation in the 
ECM” suggests that MVs in Figure 2 should be shown inside the cell as well as outside the cell. 
Authors’ response: We have revised our Figure 2 accordingly, and MVs are now shown inside the 
cell as well as outside. 
 
• Page 11 – second paragraph also refers to Figure 2 and should be noted in the text. Perhaps 
adding extra detail in the figure that is discussed in text will help readers better visualise the 
factors inducing to osteogenic transition of VMSCs. For example, “High Pi increases PiT-1 
expression, which leads to elevated levels of intracellular Pi. This further enhances Runx2 
expression and the osteogenic transition of VSMCs”, however the figure suggests it is 
extracellular. 
Authors’ response: We have revised Figure 2 accordingly.  
 
• Page 12 – State that the Atg5 deficient mice are Atg5 deficient in macrophages.  
Authors’ response: This paragraph has been removed from our revised manuscript as suggested 
by Reviewer 1. 
 
• Page 12 – second paragraph, define CKD.  
Authors’ response: We have defined CKD in our revised manuscript as chronic kidney disease 
Page 11, line 15. 
 
• Page 12 – Reference (Giachelli et al., 2005) is not found in References. 
Authors’ response: We are sorry for our mistake. It should be Giachelli et al., 2009. This reference 
has been added, Page 11, line 17. 
 
• Page 12 – Reference (Kendrick and Chonchol, 2011) is not found in References. 
Authors’ response: This reference has been added Page 11, line 18 
 
• Page 13 - (Hsu, et al., 2015) is not in References 
Authors’ response: This reference has been added, Page 11, line 21 
 
• Page 13- Define RO 
Authors’ response: RO has been defined as reactive oxygen species (ROS) Page11, line24. 
 
• Page 14 – Typo in sentence: remove full stop after “Hyperglycemia, a known inducer of vascular 
calcification. Increases…” 
Authors’ response: Full stop has been removed, Page 12, line 22. 
 
• Page 15 – Link between MVs and autophagic machinery should have it’s own subheading and 
not fall within ‘Autophagy in cardiovascular calcification’. It draws a nice summary of the origin of 
the calcification process and ties a lot of the sections together. 
Authors’ response: The Link between MVs and autophagic machinery is now in a separate 
section (section 5) in our revised manuscript, Page 13, para 3. 
 
• Page 15 – second paragraph, Be specific. “VSMCs and macrophages are the primary source of 
these calcified MVs which are released into the collagen rich matrix in the intima” should read 
“ In the context of atherosclerosis, VSMCs …” otherwise it sounds like only VSMCs and 
macrophages are the course of MVs out of all the cells that produce calcium and phosphate. 
Authors’ response: We thank the reviewer for the consideration of this point. We have modified 
our text as below (Page 13, line 17-19). 
In the context of atherosclerosis, VSMCs and macrophages are the primary source of these 
calcified MVs which are released into the collagen rich matrix in the intima. 
 
• Page 15 – second paragraph, the reference (Chistiakov, Myasoedova, Melnichenko, Grechko, & 
Orekhov, 2017) is written twice in a row but different format.  
Authors’ response: The repeat reference is removed (Page 13, line 20). 
 
5. Mitophagy in vascular calcification 
• Page 17 – Reference in text (Martin & Matthews, 1970) is not in reference list 
Authors’ response: This reference has been added (Page 23). 
 
• Figure 3 – It is not clear if the mitochondria derived vesicles in the figure are the same ones that 
contain Ca2+ and Pi. The figure suggests that MVs with Ca and Pi appear later in the 
autophagosomes and do not come from mitochondria which is what is suggested in text.  
Authors’ response: We have revised Figure 3 to differentiate between MVs and mitochondria 
derived vesicles. 
 
• Does the mitochondria need to be damaged to release mitochondria derived-vesicles or 
does the mitochondria release Ca2+ and Pi under normal conditions also? 
Authors’ response: We agree that mitochondria may release Ca2+ and Pi under normal conditions 
but damaged mitochondria accumulate and release more of them. Evidence towards this 
phenomenon can be seen in this recent study by Pei et al 2018. This reference is now cited (page 
23) and discussed in the manuscript (Page 15, line 18-20). 
 
Interestingly, Pei et al has demonstrated the release of mitochondrial electron dense granules 
from human dental pulp stem cells after osteogenic induction and their interaction with 
autolysosomes (Pei, et al., 2018). 
 
Reference:  
Pei, D. D., Sun, J. L., Zhu, C. H., Tian, F. C., Jiao, K., Anderson, M. R., Yiu, C., Huang, C., Jin, C. X., 
Bergeron, B. E., Chen, J. H., Tay, F. R., & Niu, L. N. (2018). Contribution of Mitophagy to 
Cell-Mediated Mineralization: Revisiting a 50-Year-Old Conundrum. Adv Sci (Weinh), 5, 
1800873. 
 
• Make legend for hydroxyapatite crystals and ECM 
Authors’ response: Legend for hydroxyapatite crystals and ECM has been added to revised Figure 
3. 
 
• There are no hydroxyapatite crystals being released out of the cell by the autolysosome as is 
suggested in text.  
Authors’ response: Figure 3 has been corrected with hydroxyapatite crystals present in 
autolysosomes. 
 
• Refer to each a,b,c and d step of Figure in text where mentioned. For example (a) CPP enters 
cell should be referred to on page 16 so readers can follow easily.  
Authors’ response: Each a,b,c and d step of Figure are now referred in text where mentioned. 
 
• Page 18 – ‘. Interestingly, overexpression of BCL2 Interacting Protein 3, BNIP3, which depolarises 
mitochondria and hence induces mitophagy (J. Zhang & Ney, 2009), reverses mitophagy and 
attenuates lactate induced calcification (Y. Zhu, et al., 2019)’. This sentence does not make sense. 
Are you suggesting that inhibiting mitophagy would inhibit calcification? Please clarify. 
Authors’ response: The sentence has been modified to state that enhancing mitophagy inhibits 
lactate induced calcification as demonstrated in the paper by Zhu et al 2019 (Page 16, line 10). 
Interestingly, overexpression of BCL2 Interacting Protein 3, BNIP3, which depolarises 
mitochondria and  induces mitophagy (J. Zhang & Ney, 2009) and thus attenuates 
lactate-induced calcification (Y. Zhu, et al., 2019). 
 
6. Pharmacological modulation of autophagy in vascular calcification 
• Page 18 – Tease out more. Suggests what sort of studies are needed. This is in the conclusion 
anyway but feels a bit brief. 
Authors’ response: We have elaborated a bit more both the section 7 Pharmacological 
modulation of autophagy in vascular calcification and section 8 conclusions (Page 16-18). 
 
Section 7 Pharmacological modulation of autophagy in vascular calcification, Page 17, line 14-21. 
For example, the use of a targeted autophagy inducer such as peptide TAT Beclin (Shoji-Kawata, 
et al., 2013) or the modulation of master regulator of autophagosomes and lysosomal biogenesis 
transcription factor EB (TFeb) (Napolitano & Ballabio, 2016) in ECs and VSMCs could shed more 
light into the intricate involvement of the autophagy process with the progression of VC. High 
through-put chemical screening for novel autophagy modulators is ongoing for diseases like 
cancer, neurodegeneration and viral and bacterial diseases (Panda, et al., 2019). It would be 
interesting to investigate if these novel autophagy modulators have an effect on the process of 
VC. 
 
Section 8 conclusions, Page 18, line4-10. 
Precise understanding of the role of autophagy in VC can be achieved by making novel VC mice 
models with VSMC specific deletion or overexpression of autophagy genes. It’s also crucial to 
understand the intimate interplay between Ca2+ flux, autophagy and the process of VC. In vitro 
and in vivo experiments are also required to establish the basal levels of autophagy and 
mitophagy during the entire length of the VC process. This will require the expression of 
autophagy/ mitophagy specific markers in VC mice models. This precise temporal information will 
lead to development of focused treatments in future. 
 
7. Concluding remarks 
• Page 19 – New examples are being introduced in this section which should be mentioned in 
section 6 (e.g. TAT Beclin and TFeb) 
Authors’ response: Discussion on TAT Beclin and TFeb has now been added to section 7 
Pharmacological modulation of autophagy in vascular calcification (Page 17, line14-17). 
 
• Page 19 – References (Shoji-Kawata et al., 2013) and (Napolitano and Ballabio, 2016) are not in 
references 
Authors’ response: These two references have now been added (Page 23, 24). 
 
• Are there limitations for using the pharmacological modulators mentioned that could cause 
alternative side effects in patients if used as a potential therapy? 
Authors’ response: The side effects of Rapamycin as an immunosuppressant has been added in 
our revised manuscript (Page 17, line 11-12).  
However, most of these studies are based on pharmacological modulators such as rapamycin and 
valporic acid, which may induce non-specific effects, for example rapamycin is an 
immunosuppressant (Dumont & Su, 1996). 
 
• Figures 
All figures have different font, please be consistent.  
Authors’ response: All the fonts have been standardized for Figure 1, 2 and 3. 
 
• Please fix all figures accordingly as stated in each section. 
Authors’ response: We have amended all figures accordingly. 
 
• Table 
Page 30 - (Hsu, et al., 2015) is not in References. 
Authors’ response: The reference has been added now (Page 21). 
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The autophagy pathway is a key regulator of cellular metabolism and homeostasis, and plays a 2 
critical role in maintaining normal vascular cell function. It is well recognized that autophagy 3 
can regulate endothelial cell homeostasis, vascular smooth muscle cell (VSMC) phenotype 4 
transition, and calcium (Ca2+) homeostasis in VSMCs. Emerging evidence has demonstrated 5 
that autophagy directly protects against vascular calcification (VC). Crosstalk between 6 
endosomes, dysfunctional mitochondria, autophagic vesicles and Ca2+ and phosphate (Pi) 7 
enriched matrix vesicles (MVs) may underpin the pathogenesis of VC. In this review, we 8 
summarize the current experimental evidence in understanding how autophagy maintains 9 
normal vascular cell function and its protective role against vascular calcification. We also 10 
discuss the underlying molecular and cellular mechanisms through which autophagy inhibits 11 
vascular calcification. Pharmacological modulation of autophagy may offer an exciting new 12 
strategy for the treatment of vascular calcification. 13 
 14 
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1. Introduction 1 
Autophagy is essential for health and longevity (Nakamura & Yoshimori, 2018). This catabolic 2 
pathway is initialised by a double membraned phagophore which engulfs misfolded proteins, 3 
damaged organelles or unwanted metabolites forming an autophagosome. The autophagosome 4 
fuses with single membraned acidic lysosomes, where the engulfed content is degraded into 5 
cellular building blocks, thereby, recycling the nutrients and providing a source of energy to 6 
the cells (Singh & Cuervo, 2011). Based on the membrane dynamics and the molecular 7 
machinery involved, three main types of autophagy have been identified so far, 8 
macroautophagy, chaperone-mediated autophagy and microautophagy (Cuervo & Wong, 2014; 9 
Feng, He, Yao, & Klionsky, 2014; W. W. Li, Li, & Bao, 2012). In this review we focus on 10 
macroautophagy (referred hereafter as autophagy) which could be both selective and non-11 
selective. Non-selective autophagy degrades cytoplasmic contents, however selective 12 
autophagy can degrade specific substrates like mitochondria (Lazarou, et al., 2015), ribosomes 13 
(Kraft, Deplazes, Sohrmann, & Peter, 2008), bits of ER (Wilkinson, 2019), peroxisomes (Kim, 14 
Hailey, Mullen, & Lippincott-Schwartz, 2008), bacteria (Bauckman, Owusu-Boaitey, & 15 
Mysorekar, 2015) etc. using specific autophagy receptors.  Most of the living cells perform low 16 
level of basal autophagy to maintain protein turnover and for recycling of damaged organelles, 17 
however autophagy pathway is up-regulated when the cells are challenged with stressors such 18 
as nutrient starvation (Shang, et al., 2011), hypoxia (Daskalaki, Gkikas, & Tavernarakis, 2018), 19 
reactive oxygen species (ROS) (Filomeni, De Zio, & Cecconi, 2015), protein aggregates 20 
(Menzies, Fleming, & Rubinsztein, 2015), infection (Levine & Kroemer, 2008) and increased 21 
phosphate levels (Dai, et al., 2013). In the last twenty years, autophagy has been extensively 22 
investigated as a common mechanism underpinning the development of important human 23 
diseases including cancer (White, 2015), neurodegeneration (Nixon, 2013), cardiomyopathy 24 
(Tong & Sadoshima, 2016), diabetes (Gonzalez, et al., 2011), liver disease (Rautou, et al., 25 
6 
 
2010), autoimmune diseases (Yang, Goronzy, & Weyand, 2015) and infection (Deretic, Saitoh, 1 
& Akira, 2013). Crucially, the role of autophagy in vascular calcification, a significant risk 2 
factor for cardiovascular mortality, is just emerging.  In this review, we discuss our present 3 
understanding of the important role of autophagy in the maintenance of vascular cell function 4 
and vascular calcification, and the emerging strategies to target autophagy for the treatment of 5 
vascular calcification.  6 
 7 
2. The key regulators of autophagy 8 
The autophagic molecular machinery was first elucidated in yeast followed by identification of 9 
homologues in humans (Itakura & Mizushima, 2010; Mizushima, Yoshimori, & Levine, 2010; 10 
Tsukada & Ohsumi, 1993). To date, there are more than 40 autophagy related (ATG) genes 11 
known. These genes orchestrate a highly dynamic autophagy pathway which gets activated 12 
during stress (Murrow & Debnath, 2013) (Fig 1). When nutrients are limited in the environment, 13 
the target of rapamycin TOR complex is inhibited, which results in the activation of ULK1/2 14 
complex. This complex interacts with Atg13, FIP200, Atg101, leading to phagophore assembly 15 
(Cheong & Klionsky, 2008; Cheong, Nair, Geng, & Klionsky, 2008; Mao, et al., 2013) (Fig 16 
1a). Phagophore formation is a vital step in the autophagy pathway as it leads to formation of 17 
the double membrane sequestering compartment – the autophagosome (Mizushima, Yoshimori, 18 
& Ohsumi, 2011; Suzuki, Kubota, Sekito, & Ohsumi, 2007). Several Atg proteins participate 19 
in this process including Beclin1, Vps34, Ambra1, Atg6, Atg14 and Atg38 (Z. Xie & Klionsky, 20 
2007) ( Fig 1a). After initiation of phagophore formation, the next step is its expansion and 21 
maturation. This is carried out by Atg12 and light chain 3 (LC3), the two Ubiquitin-like 22 
proteins. Atg12 forms a complex with Atg5 and Atg16L1 (also known as E3 enzyme) with the 23 
action of E1 and E2-like enzymes Atg7 and Atg10 (Nakatogawa, 2013) covalently attaches to 24 
phosphatidylethanolamine (PE) (Fig 1b) , a lipid, to from a LC3-PE complex on the surface of 25 
7 
 
the autophagosome, resulting in the formation of a mature autophagosome (Satoo, et al., 2009) 1 
(Fig 1b). The conjugation of PE with LC3 requires Atg7, an E1-like enzyme (Tanida, et al., 2 
1999), and Atg3, an E2-like enzyme (Ichimura, et al., 2000). For the efficient expansion of the 3 
phagophore and recycling of LC3-PE, Atg4, a cysteine protease (Satoo, et al., 2009) is required.  4 
These mature autophagosomes filled with cargo marked for degradation can now fuse with the 5 
lysosome, forming a fusion compartment autolysosome (Fig 1c). Cargo engulfed by 6 
autophagosome require ubiquitination and is recognised by specific adaptor molecules 7 
including p62, NBR1, NDP52, VCP and optineurin (Shaid, Brandts, Serve, & Dikic, 2013). 8 
This flagged cargo then binds to LC3/GABARAP/GATE16 family on the internal membrane 9 
of the autophagosome (Fimia, Kroemer, & Piacentini, 2013). Inside autolysosomes the cargo 10 
is degraded by hydrolases present in the acidic lumen of the lysosomes (Fig 1c). The functional 11 
role of the primary autophagy molecules has been extensively reviewed previously (Dikic & 12 
Elazar, 2018; Kaur & Debnath, 2015; Mizushima, 2007). Furthermore, autophagy pathway 13 
could also be regulated by TOR independent pathways like inositol signalling pathways (Sarkar, 14 
et al., 2005), Ca2+/calpain pathway (Williams, et al., 2008), cAMP pathway (Williams, et al., 15 
2008) etc.  It is also interesting to note that autophagy pathway, which is mainly a cellular 16 
degradation pathway is intimately linked to cell death and is different from other programmed 17 
cell death mechanisms like apoptosis, necrosis and necroptosis. Autophagy cell death is often 18 
seen associated with increased number of autophagosomes inside the cell (Yonekawa & 19 
Thorburn, 2013). However, there is a complex crosstalk between autophagy and apoptosis 20 
where the calpain-mediated cleavage of Atg5 can trigger cell death by apoptosis (Yousefi, et 21 
al., 2006). In this review we have only focused on autophagy as a cytoprotective pathway. 22 
 23 
3. Autophagy in maintenance of vascular smooth muscle cell function 24 
8 
 
Vascular smooth muscle cells (VSMCs) are the principal cellular components of blood vessels. 1 
These cell types both play a key role in maintaining blood flow, vessel tone, and are crucial for 2 
restoring vascular homeostasis during mechanical shear stress, vascular injury and blood clots 3 
(Cahill & Redmond, 2016). Crucially, autophagy is essential for the maintenance of 4 
physiological vascular cell function (Grootaert, et al., 2015; Liao, et al., 2012; Vion, et al., 5 
2017).  6 
 7 
VSMCs are the most abundant cells in the medial layer of arteries, where they maintain vessel 8 
dilation and constriction, regulating blood pressure and distribution of oxygen and nutrients to 9 
surrounding cells (Lacolley, Regnault, Nicoletti, Li, & Michel, 2012). A defining feature of 10 
VSMCs is their heterogeneity, i.e. they can switch from a contractile (quiescent) phenotype to 11 
a proliferative, synthetic (osteogenic) phenotype. VSMCs with a contractile phenotype express 12 
markers including SM-α actin, calponin and SM22α, and have decreased mobility, reduced 13 
proliferation, and lower extracellular matrix (ECM) production (Fig 2). However, following 14 
phenotypic switching they start to express markers including matrix metalloproteinase, 15 
collagenase, alkaline phosphatase (ALP), vimentin, osteopontin and Runx2 (Iyemere, 16 
Proudfoot, Weissberg, & Shanahan, 2006) ( Fig 2). The cells are now capable of moving to the 17 
intima, proliferating and enhancing ECM formation. These osteogenic VSMCs are also a 18 
crucial source of calcifying matrix vesicles (Naik, et al., 2012). This phenotypic switching is 19 
prompted by various biochemical and physical environmental cues and is seen in several 20 
conditions including atherosclerosis, diabetes, hypertension and aging (Durham, Speer, 21 
Scatena, Giachelli, & Shanahan, 2018; Lacolley, Regnault, & Avolio, 2018; Reddy, et al., 2016; 22 




PDGF (platelet derived growth factor) is a principal phenotype switching cytokine elevated 1 
during vascular injury and diseases including hypertension, atherosclerosis, and diabetes (Egan, 2 
Wainwright, Wadsworth, & Nixon, 2005; Gomez & Owens, 2012; Lacolley, et al., 2018). 3 
Studies in VSMCs have shown that PDGF stimulates cell phenotype switching, concomitantly 4 
activating autophagy (Salabei, et al., 2013) (Fig 2). The role of autophagy here is likely to be 5 
mediated through the degradation of proteins including SM-α actin, calponin and SM22α, 6 
required by VSMCs to maintain the contractile phenotype. However, genetic ablation of 7 
autophagy in PDGF-treated VSMCs is required to establish whether this phenotypic switching 8 
is entirely autophagy dependent. Further studies are also required to elucidate whether 9 
autophagy is crucial to VSMC phenotype switching in response to additional stimuli including 10 
prostacyclins, statins, amino acids and growth factors.   11 
It has been shown that increased cytosolic concentrations of Ca2+ (e.g. thapsigargin treatment) 12 
induces autophagosome formation both by TOR dependent and independent pathways 13 
(Williams, et al., 2008). However, this increase in autophagosome numbers does not leads to 14 
enhanced autophagy, rather  causes a decline in autophagic clearance via lysosomes (Ganley, 15 
Wong, Gammoh, & Jiang, 2011). The reasons behind autophagy impairment under increased 16 
calcium concentrations remains to be elucidated. Interestingly autophagy is shown to regulate 17 
Ca2+ homeostasis in VSMCs. VSMC specific deletion of Atg7 (Atg7fl/fl SM22α-Cre+) in mice 18 
causes an imbalance between Ca2+ uptake and Ca2+ release. The voltage-gated Ca2+ channels 19 
which promotes Ca2+ entry inside the cell from the extracellular space were more sensitive to 20 
depolarisation (open for Ca2+ entry from extracellular space) in autophagy defective VSMCs. 21 
On the contrary there was reduced expression of the plasma membrane Ca2+ ATPase required 22 
for removal of Ca2+ to extracellular space, leading to elevated basal levels of intracellular Ca2+ 23 
levels inside the cell (Michiels, Fransen, De Munck, De Meyer, & Martinet, 2015). This study 24 
clearly shows the crucial role of autophagy in regulating Ca2+ flux in VSMCs which further 25 
10 
 
have consequences on contractile capacity of aorta. It would be interesting to investigate the 1 
calcification levels of these cells and also if restoring autophagy pharmaceutically could 2 
normalise the Ca2+ flux and the aortic contractibility. 3 
4. Autophagy in cardiovascular calcification 4 
Vascular calcification (VC) is a significant risk factor for cardiovascular mortality and 5 
morbidity in patients with chronic kidney disease, atherosclerosis and diabetes. Previously 6 
considered a passive process due to ageing, recent advances suggest that VC is an actively 7 
regulated cell mediated process that shares many similarities with bone formation (Doherty, et 8 
al., 2003). According to its location, three principal types of vascular calcification have been 9 
reported – intimal (associated with atherosclerosis), medial (also known as Mönckeberg's 10 
sclerosis or arteriosclerosis) and calcific aortic valve disease.  The cells involved in vascular  11 
calcification include ECs, VSMCs, pericytes, calcifying vascular cells and valve interstitial 12 
cells, (Meng, et al., 2018; Pillai, et al., 2017; Yao, et al., 2013; D. Zhu, Mackenzie, Farquharson, 13 
& Macrae, 2012). These cells form a calcified matrix and undergo a bone-like osteogenic 14 
phenotypic transition in the presence of this calcifying environment. This drives apoptosis 15 
(Ewence, et al., 2008), matrix vesicle (MV) release (N. X. Chen, O'Neill, & Moe, 2018) and 16 
osteogenic differentiation in VSMCs (Liu, Lin, Ju, Chu, & Zhang, 2015) along with 17 
hydroxyapatite deposition in tissues and vessels (Lee, Morrisett, & Tung, 2012). Enriched with 18 
a concoction of calcifying enzymes, the MVs released from osteogenic cells facilitate 19 
hydroxyapatite formation in the ECM (Buchet, Pikula, Magne, & Mebarek, 2013).  20 
 21 
Calcifying VSMCs express genes like transcription factor Msx2 (Andrade, Carmo, Farias-Silva, 22 
& Liberman, 2017; Zhou, et al., 2013), Runx2 (Speer, Li, Hiremath, & Giachelli, 2010) and   23 
phosphate transporter PiT-1 (X. Li & Giachelli, 2007).  High Pi increases PiT-1 expression, 24 
which leads to elevated levels of intracellular Pi. This further enhances Runx2 expression and 25 
11 
 
the osteogenic transition of VSMCs (Fig 2). Tissue non-specific alkaline phosphatase (TNAP) 1 
expression is also central to the vascular calcification process. TNAP hydrolyses 2 
pyrophosphate (PPi), a calcification inhibitor, generating phosphate for hydroxyapatite 3 
formation in calcifying VSMCs (Sheen, et al., 2015). Furthermore, the ankylosis protein (ANK) 4 
and ecto-nucleotide pyrophosphatase/phosphodiesterases-1 (ENPP1) inhibit vascular 5 
calcification through enhancing extracellular PPi levels (Back, et al., 2018; Ho, Johnson, & 6 
Kingsley, 2000) and matrix Gla protein (MGP) inhibits vascular calcification possibly by 7 
functional inhibition of bone morphogenetic proteins (BMP-2 and BMP-4) in VSMCs (Barrett, 8 
O'Keeffe, Kavanagh, Walsh, & O'Connor, 2018; Bjorklund, et al., 2018). 9 
Exciting new evidence suggests that the autophagy pathway may play a pivotal role in 10 
regulating the key events underpinning the progression of vascular calcification. Here we 11 
discuss current experimental evidence supporting the crucial role of autophagy in regulating 12 
vascular calcification.  13 
4.1 Autophagy in CKD medial calcification 14 
Hyperphosphatemia (high serum Pi levels) regulates VC in chronic kidney disease (CKD) 15 
patients and predisposes them to progressive VC (Giachelli, 2009). Increased Pi levels induce 16 
calcification of VSMCs and  the surrounding ECM (Giachelli, 2009) and transforms the cells 17 
into an osteogenic phenotype which drives further calcification (Kendrick & Chonchol, 2011). 18 
Hyperphosphatemia enhances endothelial dysfunction through the regulation of autophagy. 19 
High concentrations of Pi inhibit TOR signalling in vitro and thus, enhance the autophagic flux. 20 
This flux offers the ECs protection from Pi-induced apoptosis (Hsu, et al., 2015). Further in 21 
vivo studies demonstrated increased, LC3 expression in the endothelial cells from CKD rats 22 
compared to sham-operated controls. Similar in vitro protective effects of autophagy has been 23 
shown in VSMCs whereby increased autophagy levels counteract VC induced by reactive 24 
12 
 
oxygen species (ROS) under high Pi levels (Dai et al., 2013). These observations are reinforced 1 
by recent in vivo experiments on DBA/2 mice which develop uremic media calcification when 2 
fed with high Pi diet. These mice show increased expression of the autophagy markers LC3-II, 3 
p62, Igfbp3, Atg16l1 in aortic VSMCs compared to control mice (Frauscher, et al., 2018). 4 
Treatment with rapamycin significantly reduced aortic calcification and release of pro-5 
inflammatory cytokines including tumour necrosis factor alpha (TNF-α) and Interleukin 6 (IL-6 
6), with enhanced survival noted in these mice (Frauscher et al., 2018).  7 
 8 
These compelling observations suggest a regulatory role of autophagy pathway in the 9 
homeostasis of Ca2+ and Pi in the population of VSMCs modulated during CKD. Furthermore, 10 
these studies establish high Pi as a stress signal for TOR, a key regulator of autophagy. 11 
4.2 Autophagy in diabetic medial calcification 12 
Patients with type-II diabetes mellitus show extensive vascular calcification with disturbed 13 
vessel wall homeostasis characterised by endothelial dysfunction and phenotypic switching of 14 
VSMCs (Casella, Bielli, Mauriello, & Orlandi, 2015; Dhananjayan, Koundinya, Malati, & 15 
Kutala, 2016; Harper, et al., 2016). Recent studies have shown that autophagy induction 16 
inhibits both the endothelial dysfunction (Fetterman, et al., 2016; Y. Xie, et al., 2011) in 17 
endothelial cells from diabetic patients and phenotypic switching of VSMCs in diabetic 18 
vascular lesions (An, Li, Wei, Li, & Xu, 2018; Qiu, et al., 2018). These studies demonstrate a 19 
protective role of autophagy in diabetic vascular disorders. 20 
 21 
Hyperglycemia, a known inducer of vascular calcification increases posttranslational 22 
modification of proteins by O-linked N-acetylglucosamine (O-GlcNAcylation) in diabetic 23 
arteries (Heath et al., 2014).  Furthermore, they show that O-GlcNAcylation of AKT (protein 24 
kinase B) leads to AKT phosphorylation and activation, thereby promoting VC. AKT 25 
13 
 
activation promotes activation of TOR and thus suppresses autophagy. Inhibition of TOR by 1 
rapamycin suppressed this O-GlcNAcylation mediated VC, suggesting a novel mechanistic 2 
role of autophagy in abrogating hyperglycemia induced VC (Heath, et al., 2014). 3 
The induction of autophagic flux through the application of tert-butyl hydroquinone (tBHQ) 4 
treatment has demonstrated an increase in aortic nuclear factor (erythroid-derived 2)-like 2, 5 
using a diabetic mouse model. Treatment with tBHQ provided atheroprotection by reducing 6 
both inflammation and the lipid content of atheroma plaques (Lazaro, et al., 2018). Selective 7 
uptake of lipid droplets by autophagosomes is an emerging pathway in cellular lipid 8 
metabolism (Zechner, Madeo, & Kratky, 2017) which will have crucial implications in 9 
metabolic disorders such as diabetes, and requires further investigation. 10 
5. Link between MVs and autophagic machinery  11 
MVs refer to nano (20-200 nm) spherical bodies which are known to bud from the plasma 12 
membrane (Fedde, 1992; Thouverey, Strzelecka-Kiliszek, Balcerzak, Buchet, & Pikula, 2009). 13 
They are made up of a lipid bilayer enriched with amorphous Ca2+ and Pi along with enzymes 14 
including TNAP, PHOSPHO 1, Na+/K+ ATPase, ENPP1, and Pit1 (Golub, 2011). MVs are 15 
typically found associated with small crystals of calcium phosphate hydroxyapatite mineral 16 
(Cui, Houston, Farquharson, & MacRae, 2016; Golub, 2009).  In context of atherosclerosis, 17 
VSMCs and macrophages are the primary source of these calcified MVs which are released 18 
into the collagen rich matrix in the intima. The MVs promote atherosclerotic calcification, 19 
directly leading to the formation of calcified plaques (Chistiakov, Myasoedova, Melnichenko, 20 
Grechko, & Orekhov, 2017). 21 
 22 
It has been shown that MV membranes are enriched in phosphatidylethanolamine (Golub, 2009, 23 
2011), which is also a main constituent of the mature autophagosome membrane (Yin, Pascual, 24 
14 
 
& Klionsky, 2016). Furthermore, TEM images of MVs reveal that they may have a single, 1 
double or a multi-layered membrane structure especially in the context of VC in atherosclerosis 2 
(Perrotta & Perri, 2017). Moreover, it is possible that, precursors of calcification such as Ca2+ 3 
and Pi are formed or processed initially within a subcellular compartment such as endosomes, 4 
multi vesicular bodies, autophagosome or autolysosome as part of intracellular control of Ca2+ 5 
and Pi homeostasis in the cellular energy landscape.  Indeed, there is recent evidence to support 6 
this view; during Ca2+ mediated DNA transfection, calcium phosphate precipitates (CPP), not 7 
the DNA, induce autophagosome formation in HEK293 cells (X. Chen, et al., 2014). The CPP-8 
DNA complex enter the cells via endosomes which interact with LC3-positive autophagosomes 9 
once inside the cytoplasm (Fig 3a). These endosomes are galectin-3 positive, suggesting that 10 
they are damaged. Furthermore, these CPP-induced LC3 positive vesicles co-localise with 11 
ubiquitin and p62, a selective autophagy adaptor. Interestingly, these vesicles also colocalise 12 
with LAMP1, the lysosomal marker, completing the autophagy cycle. Annexin-V which is a 13 
major constituent of the MV is also known to have role in formation of mature autophagosomes 14 
and is seen present on the lysosomal membrane where it participates in Ca2+ signalling (Ghislat 15 
& Knecht, 2012). It is also interesting to note that autophagosomes from calcified mouse 16 
primary osteoblasts are packed with calcified hydroxyapatite (Nollet et al., 2014). It is possible 17 
that the acidic lysosomes have a role in solubilizing this hydroxyapatite when they fuse with 18 
these autophagosomes.   19 
Recent proteomic analysis of MVs released from rat VICs by our laboratory shows expression 20 
of autophagic proteins including LAMP1, LAMP2 and LAMTOR1 (Cui, et al., 2016); LAMP-21 
I and LAMP-II are lysosomal membrane proteins required for recycling via the autophagy 22 
pathway. LAMTOR1 is part of the regulator complex on the lysosomal membrane (Colaco & 23 
Jaattela, 2017). These data suggest that MVs may be entwined with the network of autophagic 24 
vesicles either at the stage of their formation or release during the process of vascular 25 
15 
 
calcification (Fig 3a and 3c). Indeed, the recent emergence of a new field of secretary 1 
autophagy (as opposed to degradative autophagy), whereby autophagic machinery participates 2 
in conventional and unconventional secretions via plasma membrane (Ponpuak, et al., 2015) 3 
may present novel mechanistic avenues to explore (Fig 3).  4 
6. Mitophagy in vascular calcification 5 
Mitochondria have the capacity to accumulate Ca2+ in an energy dependent manner and are a 6 
crucial regulator of cellular  Ca2+ homeostasis (Glancy & Balaban, 2012). Excess Ca2+ intake 7 
by mitochondria triggers the opening of the permeability transition pores and the release of 8 
cytochrome C, resulting in cell death by apoptosis or necrosis (Izzo, Bravo-San Pedro, Sica, 9 
Kroemer, & Galluzzi, 2016). Using scanning electron microscopy, mitochondria-derived 10 
vesicles enriched with Ca2+ and Pi have been observed in calcifying skeletal cells including 11 
chondrocytes, osteoblasts and osteocytes (Martin & Matthews, 1970; Pei, et al., 2018; Sayegh, 12 
Solomon, & Davis, 1974; Sutfin, Holtrop, & Ogilvie, 1971). Indeed it has been proposed during 13 
the process of calcification  mitochondria release intracellular Ca2+ in mitochondrial- derived 14 
vesicles (MDV), which are subsequently transported to the ECM where these vesicles deposit 15 
hydroxyapatite (Boonrungsiman, et al., 2012). These MDV enriched with Ca2+ could be 16 
engulfed by autophagosomes or directly taken up by lysosomes, where they could be either 17 
degraded or released outside the cell (Fig 3d). Interestingly, Pei et al has demonstrated the 18 
release of mitochondrial electron dense granules from human dental pulp stem cells after 19 
osteogenic induction and their interaction with autolysosomes (Pei, et al., 2018). 20 
 21 
In vascular cells, oxidative stress, elevated Pi levels, inflammation, mitochondrial dysfunction 22 
and apoptosis are all intimately associated with the calcification process (Byon, et al., 2008; 23 
Giachelli, 2009; Madamanchi & Runge, 2007; Proudfoot, et al., 2001; Shanahan, 2007). In a 24 
healthy cell, dysfunctional mitochondria are cleared by autophagosomes via mitophagy; it is 25 
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not known whether the calcifying vascular cells perform enough mitophagy to remove these 1 
dysfunctional mitochondria or do they accumulate and become a source of mitochondria 2 
derived vesicles enriched with Ca2+?  Recent studies have provided exciting clues in this 3 
direction. β-Glycerophosphate (β-GP) a known inducer of  VC (Bai, et al., 2015; Shioi, et al., 4 
1995)  leads to phenotypic transition of VSMCs. Interestingly  metformin, (used to treat type 5 
2 diabetes),  has been shown to induce autophagy to restore β-GP-induced impairment of 6 
mitochondrial biogenesis and apoptosis in VSMCs, along with blocking the phenotypic 7 
transition of VSMCs (Ma, et al., 2019) (Fig 2).  Furthermore, lactate, an inducer of calcification, 8 
suppresses both autophagic flux and mitophagy in VSMCs (Y. Zhu, et al., 2019). Interestingly, 9 
overexpression of BCL2 Interacting Protein 3, BNIP3, which depolarises mitochondria and  10 
induces mitophagy (J. Zhang & Ney, 2009) and thus attenuates lactate-induced calcification 11 
(Y. Zhu, et al., 2019). These studies suggest that mitophagy is defective during the progression 12 
of vascular calcification. Defining the role of autophagy/mitophagy in restoring mitochondrial 13 
homeostasis during the phenotypic switching of VSMCs will provide important therapeutic 14 
intervention in vascular calcification disorders.  15 
 16 
7. Pharmacological modulation of autophagy in vascular calcification 17 
Several studies have investigated whether modulating autophagy by pharmacological agents 18 
can prevent vascular calcification (Table 1). Treatment with spermidine reduces lipid 19 
accumulation and necrotic core formation in atherosclerotic plaques of ApoE-/- mice, this 20 
reduction is specific to VSMCs (Michiels, Kurdi, Timmermans, De Meyer, & Martinet, 2016). 21 
Spermidine, a polyamine, is a known inducer of longevity, enhancing autophagy and 22 
suppressing necrosis in various models of aging (Eisenberg, et al., 2009). Treating mice with 23 
spermine and spermidine reverses age-related cardiac deterioration by inhibiting age-related 24 
myocardial morphology alterations, myocardial fibrosis, and cell apoptosis (H. Zhang, et al., 25 
17 
 
2017). However, the direct effect of these compounds on vascular calcification remains to be 1 
elucidated. Furthermore, treatment with estrogen attenuates arterial calcification by blocking 2 
the osteoblastic differentiation of VSMCs and this is via induction of the autophagy pathway 3 
(Peng, et al., 2017) (Fig 2). This protective effect of estrogen treatment is enhanced by the 4 
addition of rapamycin (Peng, et al., 2017) (Fig 2). Valporic acid, an autophagy inducer, has 5 
also been shown to inhibit VSMC calcification in vitro (Dai, et al., 2013). Additionally, 6 
rapamycin has been reported to inhibit vascular calcification in the DBA/2 diabetic mouse 7 
model (Frauscher, et al., 2018). Pharmacological modulation of autophagy may therefore have 8 
therapeutic efficacy for ameliorating disorders associated with VC and preventing their onset. 9 
However, most of these studies are based on pharmacological modulators such as rapamycin 10 
and valporic acid, which may induce non-specific effects, for example rapamycin is an 11 
immunosuppressant (Dumont & Su, 1996). Tissue/cell-specific ablation of the key regulators 12 
of autophagy is therefore required to delineate the specific effects of autophagy. For example, 13 
the use of a targeted autophagy inducer such as peptide TAT Beclin (Shoji-Kawata, et al., 2013) 14 
or the modulation of master regulator of autophagosomes and lysosomal biogenesis 15 
transcription factor EB (TFeb) (Napolitano & Ballabio, 2016) in ECs and VSMCs could shed 16 
more light into the intricate involvement of the autophagy process with the progression of VC. 17 
High through-put chemical screening for novel autophagy modulators is ongoing for diseases 18 
like cancer, neurodegeneration and viral and bacterial diseases (Panda, et al., 2019). It would 19 
be interesting to investigate if these novel autophagy modulators have an effect on the process 20 
of VC. 21 
 22 
8. Concluding remarks 23 
Our knowledge of the role of autophagy in cardiovascular calcification is relatively limited at 24 
this time. Nonetheless, there is crucial growing evidence that autophagy may protect 25 
18 
 
cardiovascular tissue from calcification.  It would be interesting to investigate whether 1 
membranes from autophagic vesicles contribute to the formation of MVs or if a selective form 2 
of autophagy is involved in recycling amorphous Ca2+ and Pi or hydroxyapatite (Fig 3a, b, c). 3 
Precise understanding of the role of autophagy in VC can be achieved by making novel VC 4 
mice models with VSMC specific deletion or overexpression of autophagy genes. It’s also 5 
crucial to understand the intimate interplay between Ca2+ flux, autophagy and the process of 6 
VC. In vitro and in vivo experiments are also required to establish the basal levels of autophagy 7 
and mitophagy during the entire length of the VC process. This will require the expression of 8 
autophagy/ mitophagy specific markers in VC mice models. This precise temporal information 9 
will lead to development of focused treatments in future. Furthermore, the development of 10 
specific therapeutic autophagy agents, and novel reliable methods for monitoring and 11 
measuring autophagy in patients is required.  In conclusion, targeting the autophagic molecular 12 
machinery is an attractive therapeutic strategy to inhibit progression or induce regression of 13 
vascular calcification.  14 
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Table 1:  Effect of autophagy inducers and inhibitors in VC. 1 
Model  Inducer (+)/ Inhibitor (-) 
of autophagy 






VE-cadherin-cre mice  
  
Wortmannin (-), Atg5 
shRNA (-) 
Failure of EC alignment 
under high shear stress. 
(Vion, et al., 2017) 
ECs 
  
Atg3 siRNA (-) Impaired endothelial nitric 
oxide synthase 
phosphorylation, higher 
accumulation of ROS and 
inflammatory cytokines 
like MCP-1 and IL-8 in 
response to shear stress 
(Bharath, et al., 2014) 
VSMCs PDGF (+) Induces phenotype 
switching 
(Salabei, et al., 2013) 
Cultured rat aortic rings, 
Bovine aortic smooth 
muscle cells 
Valporic acid (+) Ameliorate Pi- induced VC (Dai, et al., 2013) 
HMEC-1 cells High Pi (+) Blocks Pi induced 
apoptosis 





ATG7 KO (-) Elevated intracellular 
levels of Ca2+ 
(Michiels, et al., 
2015) 
VSMCs, calcified arteries Estrogen (+) Inhibits the osteoblastic 
differentiation of VSMCs 
(Peng, et al., 2017) 
DBA/2 mice model for 
uremic media calcification 
Rapamycin (+) Reduced aortic 
calcification, reduced 
release of proinflammatory 






Diabetic arteries Rapamycin (+) Suppressed calcification (Heath, et al., 2014) 
Diabetic mouse Aorta tBHQ (+) Atheroprotective, 
reduction in inflammation 
and lipid content  of 
plaques 
(Zechner, et al., 
2017) 
VSMCs Metformin (+) Restores mitochondrial 
biogenesis. 
(W. Q. Ma, et al., 
2019) 
VSMCs Overexpression of BNIP3 
(+) 
Attenuates lactate induced 
calcification and enhances 
mitophagy 





Spermidine (+) Reduced lipid 
accumulation and  necrotic 
core formation in 
atherosclerotic plaques 
(Michiels, et al., 
2016) 
    










Figure legends 1 
Figure 1: Overview of key molecular players in the autophagy pathway. a) Phagophore 2 
formation is triggered under cellular stress which engulfs cellular debris including damaged 3 
mitochondria, bits and pieces of ER, ribosomes etc. b) This phagophore matures into a double 4 
membrane autophagosome decorated with ATG8/LC3-PE. c) Mature autophagosomes fuse 5 
with single membrane lysosomes with variety of hydrolases in their lumen which degrade the 6 
content of the autophagosome. d) This fusion compartment is called autolysosome which 7 
returns the recycled building blocks to the cell. 8 
Figure 2: Role of autophagy in the phenotypic transition of VSMCs during the 9 
progression of VC. a) Basal levels of autophagy are required by the VSMCs for maintaining 10 
both the contractile and the osteogenic phenotype. b) Increased concentrations of PDGF and 11 
intracellular Pi induces cytoprotective autophagy to counter ROS and apoptosis associated with 12 
an osteogenic phenotype. c) Inducing autophagy using estrogen, rapamycin, metformin 13 
prevents osteogenic phenotypic switching. 14 
Figure 3: A possible crosstalk among endosomes, dysfunctional mitochondria, autophagic 15 
vesicles and MVs in VC. a) CPP or hydroxyapatite enters the cells via endocytosis and these 16 
endosomes fuse with autophagosomes and are passed on to autolysosomes.  b)  Hydroxyapatite 17 
may be degraded inside the autolysosomes. c) Or is passed on to autolysosomes packed in nano 18 
MVs, these autolysosomes fuse with plasma membrane and release of MVs to the ECM, where 19 
they aid in hydroxyapatite formation. d) Mitochondria derived-vesicles as a source of 20 
calcification could be engulfed by autophagosomes or directly taken up by lysosomes where 21 
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